-
23andMe Pivoting To Clinical Research: Could That Lead To A Turnaround For The Stock?
Tuesday, January 18, 2022 - 9:48am | 955Genetic testing company 23andMe Holding Co. (NASDAQ: ME) took the unconventional route of a SPAC deal to go public, and the stock hasn't gained much traction since it began trading on June 17, 2021. The new year saw the company announcing its diversification into drug development. Will this...